Nuvation Bio (NUVB) recently completed a $250 million offering of 0.75% convertible senior notes due 2032, drawing investor attention as the company refines its capital structure and funds its oncology development pipeline.

Nuvation Bio’s share price has risen 39.51% over the past 90 days and 18.20% over the past 30 days, while its 1 year total shareholder return of 192.75% contrasts with a year to date share price decline of 34.15%. This suggests strong long term gains alongside recent volatility around the convertible notes financing.

If this kind of financing story has your attention, it can be useful to scan other cancer and AI focused developers through our curated list of 39 healthcare AI stocks

With Nuvation Bio shares up strongly over the past year but down year to date, and the stock trading below analyst price targets and some intrinsic value estimates, is there still mispricing here, or is the market already factoring in future growth?

Most Popular Narrative: 71.3% Undervalued

The most followed narrative values Nuvation Bio at $19.70 per share, well above the last close at $5.65, framing the recent convertible notes in a much larger growth story.

Safusidenib targets a substantially larger glioma market than ROS1 lung cancer, with differentiated response data in both low and high grade IDH1 mutant disease and an FDA aligned pivotal Phase III design. This positions the asset as a potential second major commercial pillar that can accelerate long term revenue and earnings growth.

Want to see how this second pillar idea underpins that high fair value? The narrative focuses on rapid revenue expansion, margin uplift, and a rich future earnings multiple.

Result: Fair Value of $19.70 (UNDERVALUED)

However, Nuvation Bio’s story could change if safusidenib’s long Phase 3 timeline disappoints, or if rival ROS1 therapies limit IBTROZI’s uptake and pricing power.

Another View: What Multiples Say About Nuvation Bio

While the popular narrative sees Nuvation Bio as deeply undervalued, the P/S ratio tells a tougher story. The stock trades at 13.8x sales, compared with 6.8x for peers and 5.8x for the wider US Pharmaceuticals industry, even though the fair ratio is 14.8x. Is that premium a cushion or a warning if sentiment cools?

For a clearer picture of how this pricing gap could matter over time, it helps to see the full valuation breakdown and how the market might move toward the fair ratio. This includes considering the risks if sentiment swings away from Nuvation Bio in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern around Nuvation Bio, it makes sense to review the full picture quickly and form your own judgment using the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Nuvation Bio?

If Nuvation Bio has sharpened your interest, do not stop here. Use the Simply Wall St screener to spot other opportunities that could suit your approach.

• Target potential mispricing by scanning companies our tools flag as having room for upside with the 44 high quality undervalued stocks
• Prioritize resilience by reviewing companies with strong finances through the solid balance sheet and fundamentals stocks screener (48 results)
• Hunt for under followed opportunities that may not be on every watchlist yet inside the screener containing 19 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.